EP Wealth Advisors LLC Invests $311,000 in GSK plc (NYSE:GSK)

EP Wealth Advisors LLC bought a new position in shares of GSK plc (NYSE:GSK – Get Rating) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,555 shares of the pharmaceutical company’s stock, valued at approximately $311,000.

Several other large investors also recently modified their holdings of GSK. Pflug Koory LLC bought a new position in GSK in the third quarter valued at about $26,000. Householder Group Estate & Retirement Specialist LLC acquired a new stake in GSK in the third quarter valued at approximately $31,000. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after acquiring an additional 368 shares during the period. Cowa LLC acquired a new stake in GSK in the first quarter valued at approximately $45,000. Finally, CoreCap Advisors LLC purchased a new position in shares of GSK during the second quarter valued at approximately $66,000. 13.15% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. AlphaValue raised GSK to a “buy” rating in a research report on Thursday, December 8th. JPMorgan Chase & Co. boosted their price objective on GSK from GBX 1,350 ($16.45) to GBX 1,400 ($17.06) in a research note on Thursday, February 2nd. Berenberg Bank boosted their target price on GSK from GBX 1,580 ($19.26) to GBX 1,730 ($21.08) in a research report on Friday, February 10th. The Goldman Sachs Group began coverage on GSK in a research report on Sunday, February 26th. They set a “buy” rating for the company. Finally, Citigroup reduced their target price on GSK from GBX 1,975 ($24.07) to GBX 1,550 ($18.89) in a research report on Friday, December 2nd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $1,576.88.

GSK Trading Up 0.7 %

GSK opened at $34.07 on Friday. The business has a 50 day simple moving average of $35.00 and a two-hundred day simple moving average of $33.56. The firm has a market capitalization of $69.74 billion, a price-to-earnings ratio of 3.97, a PEG ratio of 1.69 and a beta of 0.65. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.91 and a quick ratio of 0.68. GSK plc has a one year low of $28.47 and a one year high of $46.97.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 13th. Shareholders of record on Friday, February 24th will be given a dividend of $0.3404 per share. This represents a $1.36 dividend on an annualized basis and a yield of 4.00%. The ex-dividend date of this dividend is Thursday, February 23rd. GSK’s payout ratio is 15.50%.

GSK Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.